|
|||
|
Multiple Sclerosis Information
Search
This Month
Favorite Links
Month Archive
|
Saturday, June 20
Clinical Study – Volunteers Needed
by
All About MS
on Sat 20 Jun 2009 09:32 AM CST
A Randomized, Double-blind, Placebo-Controlled, Escalating-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS-0777,
Administered more »
Friday, June 19
Clinical Trial - Spasticity
by
All About MS
on Fri 19 Jun 2009 08:27 AM CST
This research study will evaluate a treatment for moderate to severe spasticity associated with MS. All patients must have been on baclofen for at least four weeks prior to first visit. This study requires five visits over more »
Wednesday, June 17
Interracial Origins of MS
by
All About MS
on Wed 17 Jun 2009 01:00 AM CST
Multiple Sclerosis (MS) is a complex neurologic disease with a striking geographical distribution. In Canada, prevalence is high in Caucasians of Northern European ancestry and uncommon in North American Aboriginals, more »
Tuesday, June 16
Stem Cell Clinical Trials, Questions
by
All About MS
on Tue 16 Jun 2009 01:00 AM CST
Many readers have been wishing to know how they can be part of clinical trials for stem cell research. I have researched stem cell research trials for some time now. I cannot find even one clinical trial for stem cell research more »
Monday, June 15
Mitoxandrone - Leukemia Risk
by
All About MS
on Mon 15 Jun 2009 09:46 AM CST
Patients with multiple sclerosis who are treated with a cumulative dose of 82 mg/m[2 of Mitoxandrone (MTX) are at a 2.7 higher risk of developing acute leukemia (AL), according to a late-breaking abstract presented on April 30 more »
Sunday, June 14
Vision Deteriorates Without Sight-Related Symptoms
by
All About MS
on Sun 14 Jun 2009 11:14 AM CST
Researchers suggest that clinicians make a point of checking patients with multiple sclerosis (MS) for diminished vision even when the patients have not experienced any vision-related symptoms such as optic neuritis. The study was presented on May 3 at the more »
study - interferon beta-1a, azathioprine, & corticosteroids
by
All About MS
on Sun 14 Jun 2009 12:00 AM CST
Studies evaluating interferon beta (IFNbeta) for multiple sclerosis (MS) showed only partial efficacy. In many patients, IFNbeta does not halt relapses or disability progression. One strategy to potentially enhance efficacy is more »
Saturday, June 13
Fatigue Patients have Impaired Muscle Activation
by
All About MS
on Sat 13 Jun 2009 12:00 AM CST
To elucidate the role of central motor activation we hypothesized that patients with primary fatigue have impaired central motor function and increased fatigability as compared to secondary fatigued and non-fatigued more »
Friday, June 12
Remyelination of brain decreases with chronicity
by
All About MS
on Fri 12 Jun 2009 09:34 AM CST
To analyze and compare the extent of remyelination in lesions from patients with multiple sclerosis (MS) who have a short (early MS lesions) or a long (chronic MS lesions) disease duration and to determine the influence of more »
Causes Of MS - Tracking Them
by
All About MS
on Fri 12 Jun 2009 01:00 AM CST
Multiple sclerosis is a very complex disease of the nervous system. Thanks to the development of the new animal model, significantly improved insights into its emergence more »
Multiple sclerosis rehabilitation outcomes
by
All About MS
on Fri 12 Jun 2009 12:00 AM CST
De-identified data from the AROC database were analyzed for all rehabilitation admissions during 2003-2007, using four classes for functional level. The outcomes included Functional Independence Measure (FIM) scores and more »
Thursday, June 11
Clinical trials of multiple sclerosis therapies
by
All About MS
on Thu 11 Jun 2009 12:00 AM CST
The therapeutic goal for multiple sclerosis (MS) is to achieve a better long-term outcome. However, since available data come from short-term studies, it is important to review the evidence that current therapies more »
Wednesday, June 10
Bladder Dysfunction in a Mouse Model Evaluated
by
All About MS
on Wed 10 Jun 2009 12:00 AM CST
In multiple sclerosis (MS), demyelinating and neurodegenerative lesions develop throughout the central nervous system, which result in a loss of neurotransmission. As a result, people with MS exhibit a wide range of symptoms including dysfunction of the more »
Tuesday, June 9
Autoimmune Diseases may be Treated with Hydrangea Root
by
All About MS
on Tue 09 Jun 2009 11:18 AM CST
A drug derived from the hydrangea root, used for centuries in traditional Chinese medicine, shows promise in treating autoimmune disorders, report researchers from the Program in Cellular and Molecular Medicine and the more »
MRI measures show significant cerebellar gray matter volume loss
by
All About MS
on Tue 09 Jun 2009 12:00 AM CST
To determine the magnitude of cerebellar gray and white matter (GM and WM) atrophy in patients with clinically isolated syndromes (CIS) and MS, and their role in clinical more »
|
||
